Market Executive Summary

REPORT HIGHLIGHT
The anxiety disorders market is estimated to represent a global market of USD 18,234 million by 2028 with growth rate of 2.2%. Anxiety is defined as an excessive fear of a normal situation or an exaggerated response to a fear. Anxiety is one of the fast spreading disorder across the globe, majorly among young population. However, people often live with anxiety problem for years before they diagnose or treat with the condition which would in turn hamper the market growth to some extent. According to the American Psychiatric Association, anxiety can be categorized into phobias, acute stress disorder, panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, and post-traumatic stress disorder. Increasing prevalence of anxiety related disorders has led to high clinical urgency for adoption of various therapies and therapeutics available in the market, which is anticipated to fuel growth over the coming years. As per World Health Organization (WHO), anxiety and other form of depressions are one of the most common mental disorders affecting more than 300 million people worldwide. The number is projected to increase at constant rate during the forecast period.
In terms of drug category, the market is divided into Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs), Anticonvulsants, and Others. Among which, SSRIs and SNRIs are contributed to largest market share, capturing almost 60% share of the global market. Furthermore, segments such as beta blockers, SSRIs and others are considered to be the highest growing market segment during the coming years. This upsurge is a consequence of high stress and competitive work environment coupled with unprecedented shift in the lifestyle, such as drinking, smoking, consumption of unhealthy food, etc.
Based on therapy category the market is analysed into Transcranial Magnetic Stimulator, Electroconvulsive Therapy (ECT), Cognitive Behaviour Therapy (CBT), Fischer Wallace Stimulator, and Others. Fischer Wallace Stimulator, and Transcranial Magnetic Stimulator are the largest revenue generating segment. Collectively, these two segment recorded over USD 1,500 million revenue and are projected to dominate the market growth during the forecast period. High efficiency coupled with increasing demand of these therapies in developed regions such as North America and Europe led the market growth.
Regionally, developed countries of North America and Europe dominated the market, captured more than 70% share of the global market. Boost in research and development activities by key operating companies to introduce novel anxiety therapeutics and therapies coupled with surge in demand for effective anxiety therapeutics among end-users drives the market growth.
Furthermore, large number of therapeutics under clinical investigation in North America & Europe further support the market growth. For example, Switzerland based Adde Therapeutics initiated multi-centric, double-blinded, Phase II tiral of ADX71149 in adults affected with major depressive disorder in collaboration with Janssen Pharmaceuticals, Inc. These types of initiatives will support the market growth to great extent.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Hospitals
Manufacturers
Traders, Distributors, And Suppliers
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET,BY DRUG CATEGORY
Selective Serotonin Reuptake Inhibitors (SSRIs)
Tricyclic Antidepressants (TCAs)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Monoamine oxidase inhibitors (MAOIs)
Anticonvulsants
Others
MARKET,BY THERAPY
Transcranial Magnetic Stimulator
Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Fischer Wallace Stimulator
Others
MARKET,BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET,BY COUNTRY
Further Breakdown of The North America Market
S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America